Stay updated with breaking news from Trial Evaluating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This new data had both a consistent long-term safety and tolerability profile with the previous short-term results for the skin disease, and there were no new safety signals recorded.
SAN DIEGO, Aug. 31, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. , a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ,...
OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period OTX-TKI...
/PRNewswire/ -- Varian, a Siemens Healthineers company, announced today that the first participant has been treated in the RADIATE-VT™ clinical trial (NCT...
New INTEGUMENT-1 and INTEGUMENT-2 data show a rapid and significant reduction in itch as early as 24 hours after the first application of roflumilast cream...